Adaptimmune(US:ADAP) Newsfileยท2024-08-05 12:00Core Insights - Adaptimmune Therapeutics plc is set to report its financial results and business updates for Q2 2024 on August 12, 2024, before US markets open [2] - The company specializes in cell therapies aimed at treating solid tumor cancers, utilizing a unique engineered T-cell receptor (TCR) platform [3] Financial Reporting - The financial results will cover the second quarter ended June 30, 2024, and will be announced before the market opens on August 12, 2024 [2] - A live webcast will follow the announcement at 8:00 a.m. EDT, providing an opportunity for stakeholders to engage with the company [2] Company Overview - Adaptimmune is a clinical-stage biopharmaceutical company focused on developing cell therapies to improve cancer treatment outcomes [3] - The company's TCR platform is designed to engineer T-cells that specifically target and destroy various solid tumor types [3]